Chimeric Antigen Receptor T-cell Therapy Outcomes in T Cell/histiocyte-rich Large B-cell Lymphoma and Subsequent Treatment Strategies After Disease Progression: A GELTAMO/GETH Study

Overview

Journal Hemasphere

Publisher Wiley

Date 2025 Feb 5

PMID 39906687

Authors

Mariana Bastos-Oreiro

Gloria Iacoboni

Victor N Garces

Ana C Caballero

Nuria Martinez

Javier Delgado

Aitana Balaguer

Mi Kwon

Sonia Gonzalez de Villambrosia

Rafael Hernani

Ana Jimenez-Ubieto

Rebeca Bailen

Izaskun Zaberio

Alejandro Martin Garcia-Sancho

Pere Barba

Affiliations

Soon will be listed here.

References

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View

Bastos-Oreiro M, Gutierrez A, Reguera J, Iacoboni G, Lopez-Corral L, Terol M . Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. Front Immunol. 2022; 13:855730. PMC: 9336530. DOI: 10.3389/fimmu.2022.855730. View

Campo E, Jaffe E, Cook J, Quintanilla-Martinez L, Swerdlow S, Anderson K . The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022; 140(11):1229-1253. PMC: 9479027. DOI: 10.1182/blood.2022015851. View

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

Abramson J, Solomon S, Arnason J, Johnston P, Glass B, Bachanova V . Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2022; 141(14):1675-1684. PMC: 10646768. DOI: 10.1182/blood.2022018730. View

Locke F, Rossi J, Neelapu S, Jacobson C, Miklos D, Ghobadi A . Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020; 4(19):4898-4911. PMC: 7556133. DOI: 10.1182/bloodadvances.2020002394. View

Pophali P, Fein J, Ahn K, Allbee-Johnson M, Ahmed N, Awan F . CD19-directed CART therapy for T-cell/histiocyte-rich large B-cell lymphoma. Blood Adv. 2024; 8(20):5290-5296. PMC: 11497379. DOI: 10.1182/bloodadvances.2024013863. View

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

10.

Kwon M, Iacoboni G, Reguera J, Lopez Corral L, Morales R, Ortiz-Maldonado V . Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2022; 108(1):110-121. PMC: 9827173. DOI: 10.3324/haematol.2022.280805. View

11.

Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A . Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023; 389(2):148-157. DOI: 10.1056/NEJMoa2301665. View

12.

Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Ubieto A, Poza M, Fernanez-Caldas P . New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group. Hemasphere. 2024; 8(4):e70. PMC: 11033920. DOI: 10.1002/hem3.70. View

13.

Iacoboni G, Iraola-Truchuelo J, OReilly M, Navarro V, Menne T, Kwon M . Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy. Hemasphere. 2024; 8(5):e62. PMC: 11106798. DOI: 10.1002/hem3.62. View

14.

El Weshi A, Akhtar S, Mourad W, Ajarim D, Abdelsalm M, Khafaga Y . T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma. 2007; 48(9):1764-73. DOI: 10.1080/10428190701559124. View

15.

Schuster S, Svoboda J, Chong E, Nasta S, Mato A, Anak O . Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017; 377(26):2545-2554. PMC: 5788566. DOI: 10.1056/NEJMoa1708566. View

16.

Trujillo J, Godfrey J, Hu Y, Huang J, Smith S, Frigault M . Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021; 137(24):3454-3459. PMC: 8212512. DOI: 10.1182/blood.2020009148. View

17.

Griffin G, Weirather J, Roemer M, Lipschitz M, Kelley A, Chen P . Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2020; 137(10):1353-1364. PMC: 8555417. DOI: 10.1182/blood.2020006464. View

18.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View